Navigation Links
Genta Incorporated to Present at the BIO CEO & Investor Conference
Date:2/5/2008

BERKELEY HEIGHTS, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced today that the Company's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., will provide a company overview and update of corporate activities at the BIO CEO & Investor Conference. The presentation is scheduled for Wednesday, February 13th at 3:30 pm ET at the Waldorf Astoria Hotel, New York, NY.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. Accuray Incorporateds CEO to Speak at Piper Jaffray 19th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , September 16, 2014 BCC ... MARKET FOR STEM CELLS , the global market for ... billion by 2018, with a five-year compound annual growth ... witnessed in the Americas with growth projections of $2.2 ...      (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other ...
(Date:9/15/2014)... Cancer Immunotherapy Market : ... Therapies is a new market research report announced ... principal types of therapeutics that have become the ... immunotherapy (which is often called "immuno-oncology") in recent ... cellular immunotherapy. , The regular use of ...
(Date:9/15/2014)... made of carbon nanotubes is neat, but Rice University scientists ... nanotubes in new fibers created at Rice line up like ... chemist Angel Mart and his colleagues. , The tricky bit, ... in the journal ACS Nano , is keeping the ... fiber. , Left to their own devices, carbon nanotubes form ...
(Date:9/15/2014)... 15, 2014 Research and Markets has ... by Product, by Services, by Technology, by Application - Global ... Whole Exome Sequencing (WES) is next-generation technology used for ... exon. The exome, which is the total of all exons ... and is actually converted into proteins after translation. It is ...
Breaking Biology Technology:Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3
... 4 Immtech Pharmaceuticals,Inc. (AMEX: IMM ) ... exclusive,license to BioAlliance Pharma SA (Euronext Paris - ... maleate (pafuramidine), in,Europe for the treatment of pneumocystis ... of Human African trypanosomiasis, also known as,African sleeping ...
... Israel, December 4 Healthcare,Technologies Ltd. (NASDAQ: ... its unaffiliated and voting shareholders (approximately 90%),voted in ... the meeting, the shareholders were asked to approve ... Inc, Mac,Bioventures Inc. and Gamida for Life B.V. ...
... Biotest Pharmaceuticals,Corporation, a leading developer of ... management team as part of the formal,completion ... (Nasdaq:,NABI) and the creation of Biotest Pharmaceuticals. ... Corporation Completes Acquisition,of Nabi Biologics Business Unit," ...
Cached Biology Technology:Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 2Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 3Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 4Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction 2Biotest Pharmaceuticals Corporation Announces Management Team 2Biotest Pharmaceuticals Corporation Announces Management Team 3
(Date:9/16/2014)... As open enrollment season approaches, U.S. employees will ... 2015 benefits. According to Aon Hewitt , the ... Aon plc (NYSE: AON ), employees ... in managing their health care decisions. This increased responsibility ... understand how they can make the most of the ...
(Date:9/15/2014)... 15, 2014) The so-called central dogma of ... long provided a simplified explanation for how genetic ... , In reality, of course, the process ... articulated nearly 60 years ago by Nobel Laureate ... For one, there are multiple types of RNA, ...
(Date:9/15/2014)... to a morphine regimen can result in better pain ... reduce the dosage of the opioid needed to be ... Indiana University. , The result could bring significant relief ... often felt in the arms and legs and associated ... unmet need for better treatments for neuropathic pain," said ...
Breaking Biology News(10 mins):Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 3Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 4Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 5Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 6Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 7Scientists discover RNA modifications in some unexpected places 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... the United States are 32 times more likely to ... antibiotic, gentamicin, than others outside the poultry industry, according ... Johns Hopkins Bloomberg School of Public Health. While drug-resistant ... industrial broiler chicken environment, this is the first U.S. ...
... possum and a giant rat were recorded by scientists as ... and virtually unknown Lost World in the pristine wilderness of ... Indonesia Institute of Science (LIPI) scientists were accompanied by the ... its wildlife on an expedition to the Fojas in June ...
... the Neural Basis of Cognition (CNBC), a joint project ... have for the first time described a mechanism called ... the fly allowing stimuli to be more keenly sensed. ... the January 2008 issue of Nature Neuroscience, and available ...
Cached Biology News:Poultry workers at increased risk of carrying antibiotic-resistant E. coli 2Indonesia's 'Lost World' reveals more surprises 2Neuronal circuits able to rewire on the fly to sharpen senses 2